Stem Cell

TEAD-IN-2 is a novel, orally active inhibitor of transcriptional enhancer associate domain (TEAD) and modulates TEAD by ubiquitination and/or degradation by compounds. TEAD-IN-2 can be used for the research of a variety of diseases, disorders or conditions associated with TEAD.

NRX-252262 is a potent enhancer of the interaction between β-Catenin, and its cognate E3 ligase, SCFβ-TrCP, induces mutant β-catenin degradation, with an EC50 of 3.8 nM.

KY-02327 acetate, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor.

Phospho-Glycogen Synthase Peptide-2 (substrate) is peptide substrate?for glycogen synthase kinase-3 (GSK-3) and can be used for affinity purification of protein-serine kinases.

TDI-011536 is a LATS kinase inhibitor that can regulate the Hippo signaling pathway, with an IC 50 value of 0.76nM for LATS1.

NRX-103095 is an enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCFβ-TrCP. NRX-103095 enhances the binding of pSer33/Ser37 β-catenin peptide for β-TrCP with an EC50 of 163 nM.

NRX-252114 is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCFβ-TrCP. NRX-252114 enhances the binding of pSer33/S37A β-catenin peptide for β-TrCP with an EC50 of 6.5 nM and a Kd of 0.4 nM. NRX-252114 induces mutant β-catenin degradation.

MSC-4106 is an orally active and potent inhibitor of YAP/TAZ-TEAD. MSC-4106 inhibits TEAD1 or TEAD3 auto-palmitoylation and shows inhibitory effect on NCI-H226 tumor xenograft model.

GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC50=10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research.

Casein kinase 1δ-IN-1 (compound 822) is an inhibitor of casein kinase 1 delta (CK1δ), exhibits inhibition of greater than 5%. Casein kinase 1δ-IN-1 can be used for neurodegenerative disorders such as Alzheimer's disease research.

GSK3-IN-1 (compound 11) is a GSK-3 inhibitor with an IC50 value of 12 μM. GSK3-IN-1 can be used in the research of diabetes.

Wnt/β-catenin agonist 3 (compound 98) is a Wnt/β-catenin signalling pathway agonist. Wnt/β-catenin agonist 3 can be used for the research of osteoporosis.

(E)-Ferulic acid-d3 ((E)-Coniferic acid-d3) is the deuterium labeled (E)-Ferulic acid. (E)-Ferulic acid is a isomer of Ferulic acid which is an aromatic compound, abundant in plant cell walls. (E)-Ferulic acid causes the phosphorylation of β-catenin, resulting in proteasomal degradation of β-catenin and increases the expression of pro-apoptotic factor Bax and decreases the expression of pro-survival factor survivin. (E)-Ferulic acid shows a potent ability to remove reactive oxygen species (ROS) and inhibits lipid peroxidation. (E)-Ferulic acid exerts both anti-proliferation and anti-migration effects in the human lung cancer cell line H1299.

3-epi-Vitamin D3 (Epicholecalciferol) (Compound 4), a Vitamin D3 analogue, is a Hedgehog pathway inhibitor with an IC50 of 39.2 μM measured in U87MG cells.

ABC1183 is a selective dual inhibitor of GSK3 and CDK9 with oral activity. Its IC50 values for GSK3β, GSK3α, and CDK9/cyclin T1 are 657 nM, 327 nM, and 321 nM respectively. ABC1183 has anti-inflammatory properties as well as anti-tumor activity.

ARUK3001185 (Compound 8l) is an effective, selective, orally active Notum inhibitor that can penetrate the blood-brain barrier with an IC50 value of 6.7 nM.

Box5 TFA is an effective Wnt5a antagonist. It inhibits the Wnt5a signal and suppresses Wnt5a-mediated Ca2+ release. Box5 TFA also inhibits cell migration and has potential in melanoma research.

BRD0209 is an effective, selective, and dual inhibitor of GSK3α/β (GSK3α IC50 = 19 nM; GSK3β IC50 = 5 nM). It is also a reversible ATP-competitive inhibitor with fast kinetics (Ki values of 4.2 nM for both isoforms). BRD0209 is a tricyclic pyrazolone-fused tetrahydroquinoline compound. It has potential in researching mood disorders.

Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that can inhibit the Notch1 signal. Brontictuzumab selectively binds to the negative regulatory region of Notch1. Brontictuzumab can inhibit tumor cell proliferation and is used in research for leukemia and lymphoma.

DC-TEADin02 is an effective inhibitor of TEAD palmitylation. It inhibits TEAD palmitylation with an IC50 value of 197 nM. DC-TEADin02 can be used for developmental, regenerative, and tissue homeostasis studies.

GSK3-IN-3 is a mitophagy inducer that can induce Parkin-dependent mitochondrial autophagy. It is also a GSK-3 inhibitor with an IC50 value of 3.01 μM. GSK3-IN-3 has non-ATP and non-substrate competitive properties and has neuroprotective effects on 6-OHDA.